From NAMS 2021: The truth about aspirin and statin prescription for CVD prevention
Margo B. Minissian, PhD, shares key updates from the newest recommendations for primary prevention of cardiovascular disease in women from the ACC and AHA. Minissian is executive director, Geri & Richard Brawerman Nursing Institute at Cedars-Sinai Medical Center and the Simms/ Mann Endowed Chair of Nursing Education, Innovation and Research at Cedars-Sinai Medical Center.
Cardiovascular disease (CVD) remains the leading cause of morbidity for women in the United States. Prior to the update in 2020, published in the Journal of the American College of Cardiology, there had been no formal guidelines from the American College of Cardiology (ACC)/American Heart Association (AHA) specifically addressing CVD in women since 2011.
In her presentation at the North American Menopause Society’s (NAMS) 2021 Annual Meeting, Minissian discussed the update’s critical topics related to risk factors and treatments that have led to controversies and confusion.
Link between reproductive life span and postmenopausal muscle mass
November 30th 2023A recent study in Menopause, the journal of The Menopause Society, suggests that a longer reproductive life span and later age at menopause may be associated with a reduced risk of low handgrip strength in postmenopausal women.
Read More
S3E20: Brooke Faught, NP on sexual health, trauma-informed care, and the perks of meeting in-person
December 3rd 2021In this episode of Pap Talk, we took you with us to the North American Menopause Society's recent Annual Meeting. Sexual health specialist Michael Krychman, MD, sat down with Brooke Faught, NP, to learn more about her work at the Women's Institute for Sexual Health, her role on the NAMS Planning Committee, and her tips for talking trauma with patients.
Listen
Exogenous hormones and patients at increased risk for breast cancer
October 17th 2023This lecture, presented by Holly J. Pederson, MD, at The Menopause Society 2023 Annual Meeting, looked at combined oral contraceptives in BRCA carriers and other high-risk patients, and hormone therapy in postmenopausal gene carriers as well as other high-risk women.
Read More
